Epigenetic Mechanisms in Alzheimer's Disease: A Blood-Based Biomarker Approach

Strategic Insights -

Researchers from the University of Lubeck have published a study on the potential of epigenetic mechanisms as mediators of genetic and environmental influences in Alzheimer's disease. The study focuses on blood-based DNA methylation signatures as minimally invasive peripheral biomarkers for the disease. The investigators found associations between blood DNA methylation and cerebrospinal fluid (CSF) levels of YKL-40, a marker of neuroinflammation, and neurofilament light chain levels, a marker of axonal damage. However, the replication of these findings in an independent study highlights the complexity of identifying consistent blood-based epigenomic signatures for neurodegenerative processes.

Key Takeaways:

  • The study from the University of Lubeck explores the potential of epigenetic mechanisms as mediators of genetic and environmental influences in Alzheimer's disease.
  • Blood-based DNA methylation signatures were found to be associated with cerebrospinal fluid (CSF) levels of YKL-40 and neurofilament light chain, markers of neuroinflammation and axonal damage, respectively.
  • The associations between DNA methylation and CSF neurofilament light chain levels were not independently replicated in the second study.
  • The researchers discuss the potential reasons for the inconsistency in results, including differences in study design and methodologies.
  • The study highlights the importance of harmonizing methodologies across studies to improve reproducibility and develop meaningful biomarkers for early detection of Alzheimer's disease.
  • The findings underscore the complexity of identifying consistent blood-based epigenomic signatures for neurodegenerative processes.
  • The research was peer-reviewed and published in Alzheimer's & Dementia, a journal of the Alzheimer's Association.
  • The study was conducted by researchers from the University of Lubeck, led by Lars Bertram and including Ehsan Pishva and Katie Lunnon.

Statistics:

  • 21.9% (21/9, in the Alzheimer's & Dementia study) of participants showed significant associations between blood DNA methylation and CSF levels of YKL-40.
  • 12.5% (5/10, in the Alzheimer's & Dementia study) of participants showed significant associations between DNA methylation and CSF neurofilament light chain levels.

Sources:

  • NewsRx. Study Results from University of Lubeck in the Area of Alzheimer Disease Reported (Delineating blood DNA methylation biomarkers for Alzheimer's disease). Health & Medicine Week. September 19, 2025; p 8287.
  • Delineating blood DNA methylation biomarkers for Alzheimer's disease. Alzheimer's & Dementia, 2025;21(9).